Andros Pharmaceuticals Co (ROCO:6917) Net Cash per Share : NT$8.59 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Andros Pharmaceuticals Co's Net Cash per Share for the quarter that ended in Dec. 2023 was NT$8.59.

The historical rank and industry rank for Andros Pharmaceuticals Co's Net Cash per Share or its related term are showing as below:

ROCO:6917' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.37 Med: 2.9 Max: 2.9
Current: 2.44

During the past 5 years, the highest Price-to-Net-Cash Ratio of Andros Pharmaceuticals Co was 2.90. The lowest was 2.37. And the median was 2.90.

ROCO:6917's Price-to-Net-Cash is ranked better than
68.71% of 863 companies
in the Biotechnology industry
Industry Median: 4.11 vs ROCO:6917: 2.44

Andros Pharmaceuticals Co Net Cash per Share Historical Data

The historical data trend for Andros Pharmaceuticals Co's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co Net Cash per Share Chart

Andros Pharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

2.52

1.10

0.59

5.55

8.59

Andros Pharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Cash per Share	Get a 7-Day Free Trial			0.59	4.45	5.55	4.62	8.59

Competitive Comparison of Andros Pharmaceuticals Co's Net Cash per Share

For the Biotechnology subindustry, Andros Pharmaceuticals Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Andros Pharmaceuticals Co's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's Price-to-Net-Cash falls into.

Andros Pharmaceuticals Co Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Andros Pharmaceuticals Co's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(442.609	-	58.039	-	0)	/	44.772
=	8.59

Andros Pharmaceuticals Co's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(442.609	-	58.039	-	0)	/	44.772
=	8.59

Andros Pharmaceuticals Co (ROCO:6917) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Andros Pharmaceuticals Co Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co (ROCO:6917) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261

Website

http://www.androspharma.com

Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co (ROCO:6917) Headlines

No Headlines